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Few previous studies have focused on affective impairment after transient ischemic attack (TIA) and/
or minor stroke. the aim was to establish the prevalence, evolution and predictors of post-stroke 
depression (PSD) and post-stroke apathy (PSA) over a 12-month follow-up period. We prospectively 
included TIA and minor stroke patients (NIHSS ≤4) who had undergone magnetic resonance imaging 
<7 days. PSD was diagnosed according to DSM-5 criteria and PSA was defined based on an Apathy 
Evaluation Scale (AES-C) score of ≥37. Clinical and neuroimaging variables (presence and patterns of 
lesion, cerebral bleeds and white matter disease) were analysed in order to find potential predictors for 
PSD and PSA. Follow-up was performed at 10 days and after 2, 6, 9 and 12 months. 82 patients were 
included (mean 66.4 [standard deviation11.0] years) of whom 70 completed the follow-up. At 10 days, 
36 (43.9%) and 28 (34.1%) patients respectively were diagnosed with PSD and PSA. At 12 months, 
25 of 70 (35.7%) patients still had PSA, but only 6 of 70 (8.6%) had PSD. Beck Depression Inventory-II 
score, mini mental state examination (MMSE) and a previous history of depression or anxiety were 
predictors for PSD. While MMSE score, The Montgomery Asberg Depression Rating Scale and having 
previously suffered a stroke were also risk factors for PSA. Acute basal ganglia lesion and periventricular 
leukoaraiosis were associated with pSA while deep leukorariosis with pSD. Despite the presence of few 
or only transient symptoms, pSD and pSA frequent appear early after tiA and minor stroke. Unlike pSD, 
apathy tends to persist during follow-up.
The development of depressive symptoms is the most frequent affective complication after a stroke. Post-stroke 
depression (PSD) has been widely studied and has been estimated to affect between 29% and 33% of patients1,2. 
PSD is associated with a worse prognosis, worse functional recovery, greater difficulties for social reintegration, 
poorer quality of life and an increased risk of stroke recurrence3–5. It has also been reported that patients with PSD 
have a three to four times higher risk of mortality than non-depressed patients6.
Although apathy and depression may appear together, and the former may be a symptom or expression of 
the latter, it has been shown that apathy can also occur as an independent symptom of depression7. Unlike PSD, 
post-stroke apathy (PSA) has not hitherto received much attention, even though it affects one in three stroke 
patients, with only 40% of cases being concomitant with depression8–10. It has also been shown that PSA is con-
sistently associated with a worse level of functional recovery, poorer overall health and poorer quality of life9,11,12.
In both cases, a number of predictors have been described. However, most of the studies conducted to date 
have mainly focused on the established stroke population, excluding patients with transient ischemic attack (TIA) 
1Clinical Psychologist and Neuropsychologist. Neurology department, Hospital Universitari de Santa Maria, Lleida, 
Spain. 2Clinical Neuroscience Group of the Biomedical Research Institute of Lleida (IRBLleida), Universitat de 
Lleida, Lleida, Spain. 3University of Barcelona, Spain. MRI Research Unit, Department of Radiology, Hospital del 
Mar, Barcelona, Spain. 4Department of Clinical and Health Psychology, Faculty of Psychology at the Autonomous 
University of Barcelona, Barcelona, Spain. 5Neurology Service Hospital Universitari Mutua de Terrassa. Clinical 
Neuroscience Group of the Biomedical Research Institute of Lleida (IRBLleida). Universitat de Lleida, Lleida, Spain. 
6Psychiatrist. Biomedical Research Institute of Lleida (IRBLleida) Universitat de Lleida, Lleida, Spain. 7Stroke Unit. 
Hospital Universitari Arnau de Vilanova, Lleida, Spain. *email: fpurroygarcia@gmail.com
open
2Scientific RepoRtS |         (2019) 9:16248  | https://doi.org/10.1038/s41598-019-52721-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
and/or minor stroke. Despite minimum or complete resolution of the neurological symptoms, these patients 
remain vulnerable to these neuro-psychiatric complications13.
Although magnetic resonance imaging variables are essential not only for the diagnosis of TIA, based on its 
tissular definition14, but also for the prediction of stroke recurrence after TIA or minor stroke15, little informa-
tion is currently available about neuroimaging data and the development of PSD and PSA in these patients16,17. 
Diffusion-weighted imaging could detect signs of acute ischemia in 30% of TIA patients. Besides their transient 
symptoms, these lesions could also increase the risk of cognitive and affective impairment. A relationship has 
been also been described between the location of infarcts, the presence of white matter lesions18 and cerebral 
microbleeds8,19, and cognitive and affective impairment. Our aim was therefore to determine the prevalence, 
predictors and evolution of symptoms of post-stroke depression and post-stroke apathy in TIA and minor stroke 
patients during the first post-stroke year.
Methods
patients and study design. We developed our observational, prospective and longitudinal studies accord-
ing to STROBE guidelines20. Baseline (10 days after the onset of symptoms) and follow-up visits were performed 
at 2, 6, 9 and 12 months. The study included TIA and minor stroke patients aged from 18 to 85 years old who 
had been consecutively admitted to the Hospital Universitari Arnau de Vilanova (HUAV) between January and 
December 2015. The Scientific Ethics Committee of the HUAV approved both the study and the consent proce-
dure. We obtained written informed consent from all the patients involved. The whole process was performed in 
accordance with the relevant guidelines and regulations.
TIA was defined as a rapidly evolving focal neurological deficit with only a vascular cause and a duration of 
less than 24 h. Minor stroke was defined as an ischemic stroke with a score of ≤4 on the NIHSS21. All the patients 
were submitted to neurological examination by a stroke neurologist. We excluded patients with modified Rankin 
Scale Scores (mRS) of >3, mild cognitive impairment (MCI) or dementia diagnosed before the stroke event, life 
expectancies of less than 1 year, language barriers and/or illiteracy.
Risk factor profiles, clinical and sociodemographic characteristics, and severity (National Institutes of Health 
Stroke Scale, NIHSS score22) of stroke were all recorded. Patients were classified etiologically according to TOAST 
(Trial of Org 10172 in Acute Stroke Treatment22) criteria as due to large-artery occlusive disease, small-vessel 
disease, cardioembolism, other cause and undetermined cause. For strokes of undetermined origin, no cause 
was found despite an extensive evaluation or a most likely cause could not be determined because more than one 
plausible cause was found.
neuroimaging evaluation. An MRI was acquired using a 1.5-T whole-body imager system with 24-mT/m 
gradient strength, 300-ms rise time, and an echo-planar–capable receiver equipped with a gradient overdrive 
(Philips Intera 1.5 T, MRI scanner). A neuroradiologist, who was blind to the clinical features, established the 
presence and location of any diffusion weighted imaging abnormalities. Lesion locations of acute infarcts were 
classified as frontal lobe, temporal lobe, parietal lobe, occipital lobe, subcortical white matter, basal ganglia, thala-
mus, brain stem or cerebellum. As previously described15, patterns of lesion were defined as: MRI normality, scat-
tered pearls in one arterial territory (SPOT), multiple vascular territories, a single cortical lesion in one vascular 
territory, and a subcortical pattern. Acute ischemic lesions were also classified as lesions affecting the anterior 
cerebral artery territory, cortical medial cerebral artery (MCA) territory, deep medial cerebral artery territory, 
artery penetrating territory, posterior cerebral artery territory and brain stem or cerebellum territory.
OsiriX V.4.0 imaging software was used to calculate the total volume of the diffusion weighted imaging abnor-
mality in cubic centimetres. Leukoaraiosis was categorized into subcortical and periventricular leukoaraiosis. 
Subcortical leukoaraiosis denoted white-matter hyperintensities in the centrum semiovale and the corona radiata 
(0: absent, 1: punctate foci, 2: initial confluence of foci 3: large confluent areas). Periventricular leukoaraiosis 
indicated white-matter hyperintensities exclusively located around the lateral ventricles (0: absent, 1: caps or 
pencil lining, 2: smooth halo, 3: irregular periventricular hyperintensity extending into deep white matter). 
Cerebral microbleeds were defined as multiple ovoid foci with a marked loss of signal intensity on T2*-weighted, 
gradient-recalled echo MRI23. Cerebral microbleeds were classified into lobar (cortex and subcortical white mat-
ter) and deep (basal ganglia, internal and external capsules, thalamus and posterior fossa). In all cases, MRI was 
performed within 1 week of hospital admission (3.7 [SD 1.5] days).
Depression and apathy assessment. A mental health professional made the diagnosis of PSD based 
on information reported in two assessment questionnaires: the Beck Depression Inventory (BDI-2)24 and 
Montgomery-Asberg Depression Rating Scale (MADRS)25. The BDI-2 is a 21-question multiple-choice self-report 
inventory and is one of the most widely used psychometric tests for measuring the severity of depression. The 
MADRS is a 10-item diagnostic questionnaire which is also used to measure the severity of depressive episodes. 
Both instruments have been extensively used to study the stroke population and to determine their sensitivity and 
specificity; both have also provided satisfactory results that demonstrate their usefulness in stroke patients26–29. 
Patients diagnosed with PSD had to meet the DMS-5 criteria.
Those patients who were diagnosed with depression were referred to the psychiatrist service. The same 
psychiatrist evaluated the patients during the following week and before any medication was prescribed. He 
decided what would constitute the best medical treatments (serotonin reuptake inhibitors) based on current 
guidelines30,31.
PSA was assessed using the clinician version of the Apathy Evaluation Scale (AES-C)32, which is based on the 
current functioning of patients. This assessment contains 18 questions and is administered as a semi-structured 
interview. As in previous studies, we used a cut-off score of 37 on the AES-C to identify patients with PSA8,33.
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cognitive, functional and quality of life variables. Two screening tests were administered: the Mini 
Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA), to evaluate global deteri-
oration at the baseline level.
Functionality was evaluated using the Barthel Index (BI)34 and the modified Rankin Scale (mRS)35. The BI 
scale consists of 10 items which are used to evaluate the basic activities of daily life. A high score indicates a 
greater level of independence for the basic activities of daily living. The mRS allowed us to assess each patient’s 
degree of functional disability on a 7-level scale of severity (scored from 0 to 6). A low score indicates good func-
tionality and autonomy.
Quality of life was determined using the Quality of Life Scale for Stroke (ECVI-38)36,37. This is a 
self-administered, 38-item scale that evaluates the degree of difficulty that people encounter in different areas. 
High scores indicate greater difficulties and, therefore, a worse perceived quality of life.
Statistical analysis. Data were described as frequencies and percentages for qualitative variables, mean and 
standard deviations (SD) for normally distributed quantitative variables, and median and interquartile ranges 
(IR) for non-normally distributed variables. Bivariate analysis of baseline and 12-month main outcomes: PSD 
(yes vs. no) and PSA (AES-C ≥ 37 vs. AES-C < 37) with other study variables were performed. Qualitative varia-
bles were analysed using the Pearson’s Chi-square test, and quantitative variables using the Student’s t-test or the 
Mann-Whitney U test. The longitudinal trajectories of affectivity and apathy variables (BDI-II, MADRS, AES-C) 
were also described by non-parametric local polynomial regression (loess smoothing). Finally, we fitted multivar-
iable logistic regression models for each study outcome, both baseline and 12-months. Variables showing p < 0.1 
on univariate testing were included in different logistic-regression models that used the forward stepwise method 
to identify predictors of PSD and PSA at baseline and at 12-months. Model A only included the psychometric 
instrument scores; Model B scores from psychometric instruments, except BDI-II and MADRS (model B); and 
Model C is like model B but adding the rest of the sociodemographic and baseline clinical and neuroimaging 
variables. Model calibration was assessed with the Hosmer-Lemeshow goodness-of-fit test and the area under 
the ROC curve was obtained as a measure of the ability to discriminate. All the tests were bilateral and run at a 
significance level of 5%. All the analyses were carried out using the statistical software R 3.5.1.
Results
Sample characteristics. From the initial 130 eligible patients, 82 patients were included and 70 completed 
the follow-up (Fig. 1 – flow chart). Of the 82 patients, 42 suffered a minor stroke and 40 suffered a TIA. 48 of 
the 130 eligible patients declined to participate in the study, mainly because they refused to go to the hospital to 
do the visits. There were no significant differences between the sociodemographic characteristics of the patients 
who participated in the study and those who did not. 12 patients dropped out, basically for the same reasons as 
previous stated, during the first or second follow-up visit stage.
The mean age of the patients included in the study was 66.4 (SD 11.0) years old and 72% of them were male 
(Table 1). Hypertension was the main risk factor in 48 (68.3%) of the cases. Based on the etiological classification 
of the TOAST, 40.2% were classified as indeterminate stroke patients.
neuroimaging data. The neuroimaging features are displayed in online Supplementary Table 1 and in the 
online Supplementary Information. 44 (59.5%) of the patients had positive diffusion-weighted imaging. Most of 
the acute ischemic lesions affected the cortical MCA territory (28.4%).
Description and evolution of depression and post-stroke apathy. 29 (35.36%) patients were ini-
tially diagnosed as suffering PSD. The median scores for the BDI-II and the MADRS scores were 5.00 (IR 3.0–9.0) 
Figure 1. Flow-chart.
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and 4.0 (IR 2.0–9.0), respectively. 36 (43.90%) patients had PSA at baseline. The median AES-C scale score was 
34.0 (IR 28.0–42.8). 16 (19.5%) of the patients suffered from PSD and PSA. Table 2 shows the proportion of 
patients independently suffering from depression and apathy and also those who suffered them concomitantly, 
both at baseline and at the 12-month follow-up.
After the first 12 months of follow-up, the proportion of patients with PSD decreased significantly to 11.42%. 
In contrast, the proportion of patients with PSA remained similar to the baseline value (Figs 2 and 3). All of the 
patients who had post-stroke depression and post-stroke apathy at the 12-month follow-up were initially diag-
nosed at baseline.
Variables related to post-stroke depression. According to the bivariate analysis, at baseline and at 12 
months (Table 2 and Supplementary Tables 2 and 3), PSD patients who exhibited cases of diabetes mellitus were 
more likely to be unemployed (p = 0.029) and to have personal psychiatric histories than non-PSD patients. The 
All










N = 36 p
Sociodemographic and clinical variables
Age, mean (standard 
deviation) 66.4 (11.0) 66.6 (11.0) 65.8 (11.1) 0.751 66.8 (11.1) 65.8 (10.9) 0.691
Gender:
0.483 0.075Male 59 (72.0%) 40 (75.5%) 19 (65.5%) 29 (63.0%) 30 (83.3%)
Female 23 (28.0%) 13 (24.5%) 10 (34.5%) 17 (37.0%) 6 (16.7%)
Family status:
0.296 0.541
Married 63 (76.8%) 37 (69.8%) 26 (89.7%) 33 (71.7%) 30 (83.3%)
Widower 11 (13.4%) 9 (17.0%) 2 (6.9%) 7 (15.2%) 4 (11.1%)
Divorced/separated 6 (7.3%) 5 (9.4%) 1 (3.4%) 5 (10.9%) 1 (2.8%)
Single 2 (2.4%) 2 (3.8%) 0 (0.0%) 1 (2.2%) 1 (2.8%)
Employment status:
0.029 0.058
Employee 22 (26.8%) 17 (32.1%) 5 (17.2%) 14 (30.4%) 8 (22.2%)
Unemployed 4 (4.9%) 1 (1.9%) 3 (10.3%) 2 (4.3%) 2 (5.6%)
Retired 51 (62.2%) 34 (64.2%) 17 (58.6%) 30 (65.2%) 21 (58.3%)
Inability to work 5 (6.1%) 1 (1.9%) 4 (13.8%) 0 (0.0%) 5 (13.9%)
Level of education:
0.240 0.818Primary education 57 (69.5%) 34 (64.2%) 23 (79.3%) 31 (67.4%) 26 (72.2%)
Secondary education or more 25 (30.5%) 19 (35.8%) 6 (20.7%) 15 (32.6%) 10 (27.8%)
Occasional alcohol 
consumption 38 (46.3%) 27 (50.9%) 11 (37.9%) 0.369 13 (28.3%) 25 (69.4%) <0.001
Smoking:
0.267 0.683
Non-smoker 31 (37.8%) 18 (34.0%) 13 (44.8%) 19 (41.3%) 12 (33.3%)
Ex-smoking 28 (34.1%) 17 (32.1%) 11 (37.9%) 14 (30.4%) 14 (38.9%)
Smoking 23 (28.0%) 18 (34.0%) 5 (17.2%) 13 (28.3%) 10 (27.8%)
Diabetes mellitus 30 (36.6%) 14 (26.4%) 16 (55.2%) 0.019 16 (34.8%) 14 (38.9%) 0.879
Hypertension 56 (68.3%) 37 (69.8%) 19 (65.5%) 0.880 32 (69.6%) 24 (66.7%) 0.967
Hypercholesterolemia 37 (45.1%) 23 (43.4%) 14 (48.3%) 0.847 19 (41.3%) 18 (50.0%) 0.574
Atrial fibrillation 5 (6.1%) 3 (5.7%) 2 (6.9%) 1.000 3 (6.5%) 2 (5.6%) 0.999
Previous psychiatric disease 28 (34.1%) 12 (22.6%) 16 (55.2%) 0.006 13 (28.3%) 15 (41.7%) 0.300
Family history:
0.331 0.128Neurological disease 30 (36.6%) 18 (34.0%) 12 (41.4%) 20 (43.5%) 10 (27.8%)
Psychiatric disease 10 (12.2%) 5 (9.4%) 5 (17.2%) 3 (6.5%) 7 (19.4%)
NIHSS score at admission, 
median (interquartile 
interval)
1.0 (0.0–2.8) 1.0 [0.0–2.0] 2.0 [0.0–3.0] 0.063 1.0 (0.0–2.0) 2.0 (0.0–3.0) 0.092
Previous stroke 14 (17.1%) 9 (17%) 5 (17.2%) 0,999 4 (8.7%) 10 (27.8)% 0.047
Etiology of stroke:
0.516 0.464
Large artery atherosclerotic 18 (22.0%) 10 (18.9%) 8 (27.6%) 9 (19.6%) 9 (25.0%)
Cardioembolism 13 (15.9%) 9 (17.0%) 4 (13.8%) 6 (13.0%) 7 (19.4%)
Lacunar 18 (22.0%) 14 (26.4%) 4 (13.8%) 9 (19.6%) 9 (25.0%)
Undetermined 33 (40.2%) 20 (37.7%) 13 (44.8%) 22 (47.8%) 11 (30.6%)
Table 1. Sociodemographic and clinical variables related to post-stroke depression and post-stroke apathy 
(baseline data).
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latter exhibited higher levels of apathy, reported worse scores for quality of life (p = 0.001) and worse levels of 
cognitive performance (according to the MMSE) than non-PSD patients. BDI-II, MADRS and NIHSS scores 




follow-up N = 70
Post-stroke depression 13 (15.8%) 1 (2.2%)
   ○ TIA 4 (10%)
   ○ Minor stroke 9 (21.4%) 1 (2.5%)
Concomitant post-stroke 
depression and apathy 16 (19.5%) 7 (10%)
   ○ TIA 8 (20.0%) 2 (8%)
   ○ Minor stroke 8 (19.0%) 5 (20%)
Post-stroke apathy 20 (19.5%) 18 (25.7%)
   ○ TIA 6 (15%) 4 (11.1%)
   ○ Minor stroke 14 (33.3%) 12 (35.3%)
Table 2. Proportion of patients diagnosed with post-stroke depression, post-stroke apathy, or both.
Figure 2. Evolution of post-stroke depression. Figure shows that there was a decrease in the level of depression, 
which is shown by the BDI-II and MADRS scales. In baseline PSD patients (blue line), both scores decreased at 
12 months (the red line indicates healthy patients, without baseline PSD).
Figure 3. Evolution of post-stroke apathy. Figure shows how apathy remained stable during the first year post-
stroke; the level of apathy measured by the AES-C score did not decrease (blue line). The red line indicates 
patients without post-stroke apathy at baseline (<37 scores at AES-C).
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patients with and without PSD at baseline, either between patients who had suffered TIA or minor stroke. Fazekas 
hyperintensities in the deep white matter substance score was related to PSD at 12 months.
In the different multivariate logistic regression models (Table 3), BDI-II MMSE, personal psychiatric history, 
ECVI-38, NIHSS score and diabetes mellitus were all identified as independent predictors of PSD at baseline. 
AES-C was the only predictor of PSD at 12 months.
Variables related to post-stroke apathy. According to the bivariate analysis (Supplementary Tables 2 
and 3), employment status, NIHSS score, AES-C, BDI-II, MADRS and ECVI-38 scores were all related to PSA, 
both at baseline and at 12 months. The occasional consumption of alcohol, previous stroke, the presence of acute 
lesion in the basal ganglia and the Fazekas periventricular score were all associated with basal PSA. Cognitive 
impairment determined by MMSE and primary studies were related to PSA at 12 months. There were no sig-
nificant differences between patients with and without PSA in relation to their diagnosis (TIA or minor stroke).
In the different logistic regression models (Table 4), MADRS, previous stroke and occasional alcohol con-
sumption were predictors of PSA at baseline. MMSE and AES-C were identified as predictors of PSA at 12 months 
(Table 3). Interestingly, basal PSD was not only a predictor for PSA at baseline but also for persistent PSA. Finally, 
secondary or further education was inversely related to PSA at 12 months.
Discussion
Few previous studies have focused on the development and evolution of PSD and PSA after TIA and/or minor 
stroke. In our prospective study, most of the PSD patients improved over time. In contrast, PSA persisted 
throughout the follow-up period. Two hypotheses about this finding can be made. Firstly, it is more common to 
evaluate depression and to include apathy symptoms within the depressive syndrome. Secondly, it may be that 
patients and their families do not complain about apathy as much as they do about depression. These two factors 
can mean that PSA often goes unnoticed by clinicians38. In such cases, no specific treatment will be given to it 
and this would perhaps explain the persistence of apathy over time. Furthermore, in those cases in which it is 
treated (not those in our study), it has been noticed that apathy is more resistant to pharmacological treatments 
than depression31,38.
The two affective symptoms were apparently related. Basal apathy was associated with persistent depres-
sion and basal depression with basal apathy and persistent apathy. This relationship had also been previously 
described. It has been previously reported that depression constitutes a risk factor for the appearance of apathy as 
an independent syndrome9,10,39–41. In our sample, 19.6% of the patients with PSA also had PSD. We did not iden-
tify any patients with PSA at 12 months who did not also have PSA at baseline. PSA has not traditionally received 
as much attention as PSD. However, although these two neuropsychiatric complications may be confused, scien-
tific interest in determining the predictive factors and neuroanatomic causes underlying them has increased in 
recent years, and especially in patients with Parkinson’s disease. Our proportion of PSA and PSD is lower than in 
other studies9,42,43. The heterogeneity of reported rates of PSA and PSD could be explained by the differences in 
the evalutaion methods used. In our study, thediagnosis was rigorous and required not only a determined score 
in a specific questionnaire but also an evaluation by a mental health professional. Although we did not observe 
a relationship between diffusion-weighted imaging abnormalities and affective complications, the proportions 
of PSA and PSD were as high as those determined in previous articles that included ischemic stroke patients. In 
this sense, Turner et al. previously observed that the risk of developing fatigue, psychological impairment and 
cognitive impairment in TIA patients was significantly higher than in controls44. Interestingly, we found that 
both affective complications had specific predictors; for example, low MMSE scores predicted PSD. This obser-
vation had also been made by Snaphaan et al.42. According to several systematic reviews, patients with cognitive 
Baseline 12 m follow-up
Model A Model B Model C Model A
OR (CI 95%); p value OR (CI 95%); p value OR (CI 95%); p value OR (CI 95%); p value
BDI-II 1.35 (1.19–1.58); <0.001 — — —
ECVI-38 — 1.09 (1.03–1.16); 0.006 — —
MMSE — 0.78 (0.63–0.94); 0.014 — —
AES-C — — — 1.53 (1.03–1.35); 0.026
Personal psychiatric history — — 6.25 (1.98–22.92); 0.003
NIHSS — — 6.6 (2.12–24.55); 0.002 —
DM — — 4.04 (1.34–13.2); 0.015 —
H-L test, p-value 0.82 0.69 0.94 0.40
AUC ROC (CI 95%) 0.82 (0.72–0.92) 0.76 (0.65–0.87) 0.79 (0.69–0.89) 0.79 (0.57–1.03)
Table 3. Multivariate analysis for post-stroke depression after TIA and/or minor stroke. Abbreviations: BDI-II: 
Beck Depression Inventory; ECVI-38: Stroke Quality of Life Scale; MMSE: Mini-Mental State Examination; 
AES-C: Apathy Evaluation Scale; NIHSS: National Institute of Health Stroke Scale; DM: Diabetes Mellitus. 
H-L: Hosmer-Lemeshow; AUC: area under the curve. Model A: multivariate analysis including only scores 
from psychometric instruments. Model B: multivariate analysis including only scores from psychometric 
instruments, except the BDI-II and MADRS. Model C: multivariate analysis including sociodemographic, 
clinical, neuroimaging and psychometric instruments (excluding BDI-II and MADRS).
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impairment are four times more likely to develop depression43,44. As well as TIA and minor stroke, the severity of 
a stroke measured by the NIHSS score was also a predictor of PSD. The relationship between the severity of the 
stroke and the occurrence of PSD42,45,46 and dementia47 has also been previously demonstrated. Diabetes mellitus 
also emerged as another predictor of PSD. Although there is not much evidence to support it, this is a finding that 
has been corroborated by Altieri et al.3 and Terroni et al.43.
The relationship between personal psychiatric history and the development of PSD has been supported by 
numerous studies and systematic reviews48. There is a greater risk of depression in patients who have previously 
suffered psychiatric disease.
It was surprising to note, however, that hyperintensities were only apparent in deep white-matter substance 
scores in the bivariate analysis of PSD carried out after 12 months. No other neuroimaging variable was associated 
with the development of PSD at baseline. Even so,in previous studies, the presence of depressive symptoms had 
been associated with the presence of acute ischemic lesions and/or cerebral microbleeds19,49.
Having suffered a previous stroke was related to PSA. Although there is not much evidence to support this, 
one previous study, by Yang et al., had reached the same conclusion50. After a stroke, a previous history of having 
had a stroke is a risk factor based on damage to strategic circuits, such as the frontal-subcortical circuit. We found 
an association between the presence of acute ischemic lesions in the basal ganglia and the Fazekas periventricular 
scale score in patients with basal apathy. Cortical atrophy has previously been strongly associated with symptoms 
of apathy41 and also with a reduction in white-matter integrity51,52 or white-matter hyperintensities located in the 
right hemisphere40. According to recent systematic reviews, the association between PSA and the location and/or 
size of the lesion cannot yet be clearly established9,53.
Similarly to with PSD, and in line with previous literature11,12,33,38,51,54, the persistence of apathy was associated 
with global cognitive impairment. The level of education was another factor that predicted apathy. Patients with 
only primary or lower levels of education faced a greater risk of suffering persistent apathy at 12 months after 
stroke than those with higher levels of education. Caeiro et al. had previously reported a similar relationship55.
Unlike its relationship with cognitive impairment and dementia, the role that alcohol plays in the development 
of apathy has previously not received very much academic attention. Numerous studies have analysed the effects 
of alcohol consumption on cognitive performance, but this still remains a controversial issue56,57. Considering the 
fact that the relationship between apathy and cognitive deterioration has now been demonstrated, it is possible 
to hypothesize that the effect of alcohol on apathy could be mediated by the effect that its consumption has on 
cognitive performance and that, in turn, this may affect the appearance of symptoms of apathy.
The limitations of our research that should be highlighted include the size of the cohort used, which limited 
the possibility of generalizing our results. In addition, the small sample limited the possibility of conducting an 
exhaustive study of the correlation between the different anatomical regions and the development of PSA or PSD. 
Moreover, no sample size calculation was performed. In order to make a complete evaluation, we performed sev-
eral different tests. This increased the number of variables in the statistical analysis and consequently made some 
of the interpretations more difficult. This may have also increased the risk of type I error due to multiple testing. 
The excess of analysed variables in contrast to the small sample size could have also affected results of the regres-
sion analysis. An important limitation was the fact that we did not analyse the effect of antidepressant treatment. 
Finally, it should be added that we did not include a control group. This limited our ability to determine whether 
PSD or PSA was directly related to the ischemic event, or if this was a reactive phenomenon.
In conclusion, our research is one of the few longitudinal studies to have exclusively focused on depression 
and apathy after TIA and minor stroke. Interestingly, although individuals with TIA do not have any persistent 
functional deficits after stroke, they do have neuropsychiatric complaints such as PSA and PSD, which deserve 
clinical attention. Our findings have allowed us to extend the existing scientific evidence about the risk factors 
Baseline 12 m follow-up
Model A Model C Model A Model C
OR (CI 95%); p value OR (CI 95%); p value OR (CI 95%); p value OR (CI 95%); p value
MADRS 1.18 (1.06–1.32); 0.0034 — — —
PSD — 3.43 (1.16–11.3); 0.0321 — 4.34 (1.08–19.8); 0.0433
MMSE — — 0.78 (0.58–0.99); 0.0587 —
AES-C — — 1.25 (1.14–1.42); <0.0001 1.25 (1.14–1.42); <0.0001
Secondary education or more — — — 0.19 (0.03–0.93); 0.0559
Occasional alcohol 
consumption — 8.42 (2.94–27.8); 0.0002 — —
Previous stroke — 5.0 (1.31–23.03); 0.0249 — —
H-L test, p-value 0.97 0.43 0.49 0.17
AUC ROC (CI 95%) 0.69 (0.58–0.81) 0.79 (0.69–0.89) 0.87 (0.78–0.97) 0.88 (0.79–0.97)
Table 4. Multivariate analysis for post-stroke apathy after TIA and/or minor stroke. Abbreviations: MADRS: 
Montgomery-Asberg Depression Rating Scale; PSD: Post-Stroke Depression; MMSE: Mini-Mental State 
Examination; AES-C: Apathy Evaluation Scale. H-L: Hosmer-Lemeshow; AUC: area under the curve. Model 
A: multivariate analysis including only scores from psychometric instruments. Model C: multivariate analysis 
including sociodemographic, clinical, neuroimaging and psychometric instruments (excluding BDI-II and 
MADRS).
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associated with the development of PSD and PSA. Depression appeared to be relatively high at the acute stage 
after TIA and minor stroke but, in contrast to apathy, to generally decrease during the follow-up period. Further 
research is needed to establish the optimal management procedure to help prevent the development of these 
neuropsychiatric complications. New research should be focus in the explanation and treatment of the persistent 
PSA that emerged as the most clinical relevant affective impairment in these patients.
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